Background Based on rodent studies, group II metabotropic glutamate receptors (mGluR2
and mGluR3) were suggested as targets for addiction treatment. However, LY379268 and …

Rationale Numerous medication development strategies seek to decrease nicotine
consumption and prevent relapse to tobacco smoking by blocking glutamate transmission …

Pre‐clinical studies suggest that negative allosteric modulators (NAMs) of the metabotropic
glutamate receptor subtype 5 (mGluR5), including 2‐methyl‐6‐(phenylethynyl) pyridine …

Rationale Most habitual smokers find it difficult to quit smoking because they are dependent
upon the nicotine present in tobacco smoke. Tobacco dependence is commonly treated …

Background: Abundant evidence at the anatomical, electrophysiological, and molecular
levels implicates metabotropic glutamate receptor subtype 5 (mGluR5) in addiction …

Rationale Group II metabotropic glutamate receptors (mGluR2 and mGluR3) have been
suggested to play an important role in mediation of drug-reinforced behaviors, as well as in …

Rationale The metabotropic glutamate receptor subtype 5 (mGluR5) has been reported to
be critically involved in drug reward and addiction. Because the mGluR5 negative allosteric …

Although few medications have been approved by the US Food and Drug Administration
(FDA) to assist people to quit tobacco smoking, there are no FDA-approved medications to …

Compounds that modulate metabotropic glutamate subtype 2 (mGlu2) receptors have the
potential to treat several disorders of the central nervous system (CNS) including drug …

Tobacco smoking, driven by the addictive properties of nicotine, continues to be a worldwide
health problem. Based on the well-established role of glutamatergic neurotransmission in …